



Childhood cancer can be cured in a good proportion of patients, but outcome rates are still unsatisfactory 
for specific cancer types and for resistant or relapsed disease. Collaborative clinical research is required for 
further outcome improvement as well as easier access for children to innovative treatments. Moreover, clini-
cal care standards and clinical research infrastructure in Belgium should be optimised and structurally finan-
ced to reach the level proposed by international professional and scientific organisations. In this strategic 
plan, obstacles are analysed, and solutions for improved childhood cancer care and clinical research in 
Belgium are proposed. 
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INTRODUCTION
Since the first successful treatments of paediatric cancer pa-
tients, considerable improvement in patient survival rates 
has been achieved. Currently, 80-90% of patients survive 
after five years, due to international collaborative clinical re-
search. The area of paediatric haematology-oncology (PHO) 
is small in terms of patient numbers, but extremely diverse 
as it covers at least 60 different types of cancer in a popula-
tion ranging from new-borns to teenagers and young adults. 
Today, as our biological understanding of cancer has im-
proved, and biomarker analysis is becoming available, the 
field is even more heterogeneous, underscoring the impor-
tance of multicentre and international scientific collaboration. 
However, continued improvement in paediatric cure rates 
has stagnated in the last fifteen years while very few in-
novative cancer treatment options have become routinely 
available for children and adolescents, in contrast to the sit-
uation for adults. In adult cancer, lower survival rates jus-
tify innovative treatments for a larger population, whereas 
in children innovative treatments are so far mostly justified 
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only for exceptional cases of treatment resistance or relapse. 
Nevertheless, the long-term effects of paediatric cancer can 
be more devastating than in adults, since it occurs early in 
life and the late effects from disease and treatment continue 
to develop over several decades, further justifying the con-
tinued need to improve treatments and outcomes. 
The practice of paediatric oncology is unique as optimal treat-
ment ideally includes participation of patients in clinical trials, 
meaning that standard of care is, in most instances, treatment 
in the framework of a(n) (inter)national academic clinical 
trial. This is an unusual situation, differing from the situa-
tion of adult oncology. As paediatric cancer is inherently rare, 
treatment of a maximal number of patients in clinical trials 
is required to include sufficient numbers of patients to gain 
meaningful results regarding biological insights and thera-
peutic and prognostic improvements. However, these trials 
are not funded by the pharmaceutical industry and often rely 
entirely on charity funding from the participating countries. 
Most innovative drugs and treatments in paediatric oncolo-
gy have been brought forward by investigator-driven clinical 
trial groups. Worldwide, several professional organisations 
were founded, some national, some international (such as the 
International Society for Paediatric Oncology [SIOP]). The 
European branch of SIOP (SIOPe) assembles established na-
tional PHO societies such as the Belgian Society for Paediatric 
Haematology and Oncology (BSPHO) and consists of sever-
al disease-specific working groups that are the driving force 
behind numerous European multicentre trials.  
Because of the low absolute incidence of childhood cancer, 
Belgian centres participate in international clinical trials, in 
the framework of these scientific groups. Considerable ef-
fort has been made by Belgian centres to facilitate access to 
clinical trials and to run these trials conform the current 
regulations. The Belgian government has supported this at-
titude by providing support in the Belgian Cancer Plan. This 
cancer plan, implemented in 2010 and described in a Royal 
Decree on April 2nd, 2014, in the Belgian Statute Book (Sta-
atsblad/Moniteur Belge), defines the minimal staffing stan-
dards for specialised and satellite PHO sites in Belgium. 
Nevertheless, even if the cancer plan has allowed for sig-
nificant progress in the organisation and staffing of pae-
diatric oncology teams in Belgium, requirements and 
developments on European level have moved further. 
According to the publication of the SIOPe Strategic Plan, the 
FIGURE 1. Five-year survival for acute lymphoid leukaemia diagnosed in 2000-2007 in European children by country.2
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actual Belgian outcome results for acute lymphoblastic leu-
kaemia (ALL) in children, while being acceptable, seem to 
compare somewhat unfavourably with other Western Eu-
ropean countries. These results have to be interpreted with 
caution, as it is not clear if survival registration in other Eu-
ropean countries is done in the same rigorous way as in the 
Belgian Cancer Registry (Figure 1).1-3 International compari-
son data, recently analysed in the Concord-3 study, show ex-
cellent outcomes for ALL and lymphoma in Belgium but give 
the impression of some stagnation in further prognosis im-
provement as far as brain tumour outcomes are concerned.4 
As Belgium is a small country, the organisation of optimal 
access to innovative treatments and early phase clinical tri-
als for Belgian paediatric oncology patients faces significant 
hurdles and is generally more limited than in large European 
countries as Germany, France and the UK. We describe the 
reasons behind this situation by analysing the current state 
of paediatric oncology care in Belgium, the differences with 
other European countries and the current requirements. We 
provide proposals to align Belgian paediatric oncology care 
and clinical research with the European standards.
EUROPEAN STANDARDS OF CARE  
FOR CHILDREN WITH CANCER AND 
COMPARISON WITH THE CURRENT 
SITUATION IN BELGIUM
In 2009, SIOPe published a reference document online enti-
tled ‘European Standards of Care for Children with Cancer’, 
which led to the publication by Kowalczyk et al. in 2014.5 It de-
scribes the minimal requirements needed to provide optimal 
care to paediatric oncology patients, in terms of infrastructure 
as well as common work practices. Centres participating in 
clinical trials should adhere to these requirements in order to 
obtain comparable results and common outcomes.
For medical staff, the SIOPe document describes a re-
quirement of two full-time paediatric oncologists per 30 
new paediatric oncology diagnoses per year, with a high-
er ratio if the centre has a stem cell transplant activity. 
Since the implementation of the Belgian Cancer Plan in 2010, 
Belgian centres receive funding to fulfil most requirements 
concerning nursing and paramedical staff, although this en-
velope is fixed and does not follow indexation or inflation. 
The medical standards described in the Belgian Cancer Plan 
require two staff members for a centre with less than 50 di-
agnoses per year; four physicians for centres with more than 
50 diagnoses per year plus two extra physicians in transplant 
centres. This is in accordance with the minimal medical staff-
ing requirements across Europe as described by SIOPe. The 
Cancer Plan, however, does not provide criteria for centres 
treating more than 60 new patients per year (as those cen-
tres would require more than four physicians according to 
SIOPe requirements), does not consider the care for refrac-
tory or (multiple) relapsing patients nor for innovative treat-
ments and does not finance physician’s salaries. Despite the 
recent recognition of PHO as a subspecialty of paediatrics, 
with adjusted INAMI/RIZIV nomenclature, hospitals are still 
struggling to financially justify this absolute minimal num-
ber of paediatric oncologists. In addition, the minimal Euro-
pean standards described compare unfavourably with what 
has been studied and adopted as staffing requirements in 
Canada, where medical staff requirements correspond to ap-
proximately twice the number of physicians working in our 
Belgian centres.6 
The SIOPe standards further describe the need for govern-
ment or insurance companies to fully reimburse the costs 
of the treatment according to the recommended therapeutic 
programme, including standard of care drugs used ‘off-label’. 
In Belgium, registration for a specific PHO indication or pae-
diatric age group is often lacking for chemotherapeutic and 
supportive care drugs commonly used as standard of care, 
leading to routine off-label use of these drugs in children. As 
in Belgium, reimbursement is often based on registration cri-
teria, considerable financial difficulties can arise.  
European Reference Networks (ERNs) are the European 
Union’s initiative that will make national health systems co-
operate in the interest of patients. The newly created ERN 
on Paediatric Cancer (ERN PaedCan) and its subdivisions 
contain several large, Belgian treatment centres. It aims at 
reducing inequalities in childhood cancer survival by pro-
viding high-quality, accessible and cost-effective cross-bor-
der healthcare to European children and adolescents with 
cancer. PaedCan will also implement eHealth technologies 
and improve interoperability across different institutions. 
Especially for rare cancers, this initiative will result in the 
centralisation of patient care and hence expertise. This is 
further enhanced by the PARTNER initiative, which is a 
three-year long project part of PaedCan, that aims to cre-
ate a Paediatric Rare Tumour European Registry dedicated 
to children and adolescents with very rare tumours, linking 
existing national registries. 
Since 2010, Action 12 of the Cancer Plan provides 191,240 euros 
per year for ‘the stimulation of research in PHO and for network-
ing between centres’. This was the incentive for the founda-
tion of the National Coordination Cell Clinical Trials in 2011. 
The goal of the coordination cell is the advance-
ment of clinical research in paediatric oncology in Bel-
gium through support of administrative burden of 
clinical trials, better registration of childhood cancer in 
Belgium, improved networking between centres and co-
ordination of clinical research efforts between centres. 
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The coordination cell is led by a coordinating physician (0.1 
FTE) and funds a full-time collaborator at the Belgian Cancer 
Registry who specifically works on paediatric cancer regis-
tration. The principal activities of the coordination cell con-
sist of administrative and logistic support of clinical trials in 
the Belgian centres (Clinical Trial Cell), with 1.5 FTE col-
laborators based in three different PHO centres. This sup-
port is currently limited to academic clinical trials with no 
or very limited central funding, executed in the frame of 
international collaborations. More recently, data monitor-
ing, grant applications and centralising severe adverse events 
have been added to the task list of the Clinical Trial Cell. The 
first studies prepared and supported by the Clinical Trial Cell 
opened and included patients in 2012. More than twenty tri-
als opened with the support of the coordination cell so far. 
Since the launch of the Clinical Trial Cell, the opening of an 
academic late phase clinical trial has become more feasible 
for the PHO centres. Nevertheless, there is still no structural 
budget to cover the costs of academic clinical research. This 
concerns on the one hand issues of reimbursement of off-la-
bel, yet well-established standard of care therapies and on the 
other hand costs of no-fault insurance, pharmacy fees, data 
collection, pathology/imaging review – which serves as quali-
ty control and allows clinical benchmarking in the European 
context – biobanking, etc. All clinical trials, including academ-
ic late phase clinical trials, require rigorous data monitoring.7 
Consequently, implementing these late phase clinical trials, 
which provide access to best current care to patients, in the 
Belgian PHO sites, requires additional staff and financing. 
All Belgian paediatric oncology centres employ at least one 
clinical trial manager, usually funded by charity sources. 
These local trial managers are responsible for support of the 
local investigators, the local trial initiation (introduction eth-
ical committee, budget, contracts, etc.) and implementation, 
data management, safety reporting, etc.
In comparison, ‘Stichting Kinderoncologie Nederland’ (SKI-
ON), which is the Dutch counterpart of the coordination cell 
and which is funded by the health insurance system in the 
Netherlands, employs 30 clinical trial managers located at 
the centres and approximately 40 people based at the cen-
tral office: 13 in the clinical trial centre, 10 in administra-
tion, 13 in the laboratory, 1 statistician, 1 IT manager and 3 
managers involved in quality of data and the late effects proj-
ect.8 SKION’s annual budget is around 4,000,000 euros/year.
EARLY-PHASE CLINICAL TRIALS IN 
PAEDIATRIC ONCOLOGY IN BELGIUM 
Children with specific subtypes of cancer or with (multi-
ple) relapse(s) or refractory disease may be eligible for (in-
dustry-sponsored or academic) early-phase clinical trials 
(ECTs), typically triggered by a paediatric investigation plan 
under the EU Paediatric Regulation.7,9 Nevertheless, still very 
few therapeutic innovations in cancer are actually reaching 
children because of the possibility to obtain waivers for pae-
diatric drug development in the context of the Paediatric Reg-
ulation, and because of delays while waiting for adult results, 
which are not relevant for paediatric cancer, and the inappro-
priate translation of the adult situation to children.10
Today, participation in an innovative treatment trial is rele-
vant for a number of paediatric cancer patients although rare-
ly being life-saving, since this is usually not the aim of such 
early-phase pharmacokinetic and safety trials. Currently, on-
ly a small fraction of those early-phase industry-sponsored 
trials are recruiting in Belgium. To enrol or explore possi-
bilities for enrolment in such trials, children with advanced 
cancer may have to travel abroad. The financial burden for 
the family can be substantial, since the study-sponsor only 
covers study-related costs and not the costs for supportive 
care, travel and interim housing. Moreover, the emotional 
and social burden for these families can be unacceptable. 
Administrative and insurance hurdles are often substantial. 
Nevertheless, some first line late-phase clinical trials con-
tain a treatment window in which an innovative drug 
is used and where the same standards and regulations 
as for an early-phase trial are applicable. This means 
that the implementation of these treatment opportu-
nities in Belgium is imperative to ensure optimal care. 
Altogether, current regulations, rising standards and grow-
ing demands of clinical trial operations increasingly require 
resources and infrastructure that are currently not readily 
available in Belgium. 
The Paediatric Oncology Department of the Ghent Universi-
ty Hospital, as Innovative Therapies for Children with Can-
cer (ITCC; see below) institution, conducts ECTs, mainly in 
the area of paediatric malignant haematology, while oth-
er paediatric/haematology departments of large centres are 
also conducting early-phase trials in the framework of ear-
ly-phase facilities in their hospitals, aiming to increase the ca-
pacity for ECT access for Belgian patients within the country. 
Nevertheless, many Belgian paediatric oncology patients in 
advanced, relapsed or refractory disease situations for which 
no standard treatment is available, still have no access to in-
novative treatments in the frame of an ECT. 
SITUATION IN OTHER EUROPEAN 
COUNTRIES 
Medicine reimbursement and health care financing systems 
vary widely across Europe. In our neighbouring Western Eu-
ropean countries, there is, through a combination of public 




stantial structural funding to support paediatric oncology 
clinical research infrastructure (such as the ‘programme hos-
pitalier de recherche clinique’ [PHRC] in France, National 
Health Service [NHS] in the UK, etc.). All patients benefit 
from such infrastructure, from those receiving initial stan-
dard treatment to those with advanced disease enrolling in 
early-phase industry-sponsored trials, and it is an asset to at-
tract the interest of pharmaceutical companies selecting sites 
for their European studies. 
The Innovative Therapies for Children with Cancer con-
sortium was created in 2003 as a non- profit organisation 
under the French Law. It gathers 56 European paediatric/
oncology departments with expertise in conducting ECTs 
for children and 22 European research laboratories. The 
aim is to coordinate the development of novel therapies 
for children with cancer, in cooperation with regulatory 
bodies, pharmaceutical enterprises, parents and patients. 
Other ECTs are being conducted in sites with early-phase 
trial expertise outside the ITCC network through direct in-
teraction between the pharmaceutical industry and the sites. 
PROPOSAL 
We propose to expand and professionalise the existing sup-
port structure for late-phase paediatric oncology clinical tri-
als in Belgium (BSPHO Coordination Cell Clinical Trials), to 
align our capacity and opportunities for patients with what 
is available in our neighbouring countries. We propose the 
establishment of a cost-effective, state-of-the-art, integrat-
ed paediatric oncology clinical trial infrastructure to sup-
port innovation in this area with substantial medical need 
in Belgium. 
We identified the need to engage additional clinical trial man-
agers, an accountant for the overview of grants and financial 
management, an administrative support professional, a legal 
advisor, an IT specialist and clinical trial monitors. Local clin-
ical trial managers should be funded at a ratio of at least 1 per 20 
new diagnoses per year, meaning ranging from 2 to 6 per centre. 
Moreover, a central funding agency that can review the sci-
entific merits of a certain trial and can fund all non-struc-
tural costs related to a specific trial (such as central review, 
transport and molecular analysis of samples and other costs) 
could streamline the funding applications. Currently, trials 
can only be funded for a short period of time, sometimes 
even separate funding application submissions are needed 
for the different Belgian regions. Such a centralised funding 
agency would enhance the cost-efficiency of the personnel 
involved in the preparation and support of the clinical tri-
als significantly. Several European countries, such as France 
and the UK are organised in this way (PHRC, UK Children’s 
Cancer Study Group).  
Considering the development of a more extensive ECT ac-
tivity (industry and academic) in Belgium, the Belgian cen-
tres have agreed in a first step to organise teleconferences for 
ECT. These teleconferences take place within one week after 
an inquiry to explore the feasibility of an ECT, and partici-
pants from all centres are invited. During these teleconfer-
ences, the participants discuss the trial, feasibility and utility 
in Belgium, explore competing trials and aspire to conclude 
on one or more centres that will accept the trial and the com-
mitment of the other centres to refer their eligible patients. In 
this way, we aim to prioritise trials, based on their scientific 
merit and potential benefit for patients and centralise the ef-
fort and expertise needed for conducting these trials. 
Several centres are developing ECT activities, thus enhanc-
ing ECT capacity for children with cancer, without undue 
competition between the centres following the commitments 
made in the teleconference as described. The collaboration 
between these centres and central support from the exist-
ing coordination cell is being organised. Potential eligible 
patients for early- or late-phase trials will be discussed in 
weekly national teleconferences, provided sufficient support 
can be secured to organise these meetings. For these cen-
tres, a dedicated local physician responsible for clinical tri-
als should be funded, for the supervision of early- and/or 
late-phase clinical trial activities. For each centre that devel-
ops ECT activities, at least one paediatric clinical trial nurse 
and a pharmacist should be funded. Ideally, one clinical re-
search coordinator, one data manager and a part-time ad-
ministrator/accountant should also be available per centre. 
Beside the development of this clinical trial infrastruc-
ture, drugs that are standard of care in these trials should 
be reimbursed. It is no longer acceptable that standard of 
care treatment for paediatric oncology patients is fund-
ed by charity money, as is still too often the case today. 
Furthermore, clinical staffing levels required to secure 
this level of care and development need to be structur-
ally funded as it is part of what is considered standard of 
care in the international paediatric oncology community. 
These measures would allow the Belgian centres to optimise 
their quality of care, improve outcome levels and align clin-
ical research activities in late-phase clinical trials with Euro-
pean standards. It would create optimal access to early-phase 
trials with new compounds for all types of relapsed or refrac-
tory paediatric cancer and improve the infrastructure need-
ed to provide all of the above. 
CONCLUSION
Despite the recent improvements in the organisation and ex-
ecution of late-phase multicentre clinical trials in paediatric 
oncology in Belgium, resources are limited compared to oth-
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er European countries. Current medical and supportive staff 
levels, while committed to provide the required high stan-
dards of clinical care as well as early- and late-phase clinical 
trial opportunities for patients, are insufficient to ensure con-
tinued adhesion to developments on the international level. 
The Belgian National Cancer Plan has permitted the align-
ment of paramedical staffing of paediatric oncology centres 
to European Standards, but medical staffing and clinical re-
search support is currently still suboptimal, which is of great 
concern to all stakeholders involved. With minimal means, 
the BSPHO has created a coordination cell for clinical tri-
als in paediatric oncology in Belgium, which is functioning 
very well and has significantly improved the preparation of 
late-phase clinical trials. However, funding for conducting 
clinical trials is difficult to obtain, while costs are increasing 
due to increasing regulatory requirements. Nevertheless, this 
structure is solid and can be expanded to answer to current 
limitations in clinical trial execution, ECT availability and 
childhood cancer outcomes, if given adequate financial means. 
Continued and additional efforts are required to achieve the 
level of care and innovation comparable to our neighbour-
ing countries. Structural funding for standard of care drugs, 
used off-label in paediatrics, should be provided. 
REFERENCES
1. Vassal G, Schrappe M, Pritchard-Jones K, et al. The SIOPe Strategic Plan. A Eu-
ropean cancer plan for children and adolescents. J Cancer Policy. 2016;8(6):17-32. 
2. Gatta G, Botta L, Rossi S, et al. Childhood cancer survival in Europe 1999-
2007: results of EUROCARE-5 – A population-based study. Lancet Oncol. 
2014;15(1):35-47. 
3. Belgian Cancer Registry. Cancer in Children and Adolescents. 2013. Availa-
ble from http://www.kankerregister.org/media/docs/publications/CancerInc-
Bel2010-ChildrenAdolescents.pdf.
4. Allemani C, Matsuda T, Di Carlo V, et al. CONCORD Working group. Global sur-
veillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individ-
ual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 
population-based registries in 71 countries. Lancet. 2018;391(10125):1023-75. 
5. Kowalczyk J, Samardakiewicz M, Fitzgerald E, et al. Towards reducing ine-
qualities: European Standards of Care for Children with Cancer. Eur J Cancer. 
2014;50(3):481-85.
6. Halton J, Hand J, Byron P, et al. Establishing physician to patient ratios and 
predicting workforce needs for Canadian pediatric hematology-oncology pro-
grams. Pediatr Blood Cancer. 2013;60(4):564-69.
7. The European parliament and the council of the European Union. EU Clinical 
trial Directive, Regulation (EC) No 1901/2006 of the European Parliament and of 
the Council of 12 December 2006 on medicinal products for paediatric use and 
amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 
2001/83/EC and Regulation (EC) No 726/2004 , Official Journal L 378. 2006. 
Available from  https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/
reg_2006_1901/reg_2006_1901_en.pdf. 
8. SKION. Jaarverslag SKION 2015. Available from http://metacultura.nl/
SKION2015/.
9. European Commission. State of Paediatric Medicines in the EU. 10 years of 
the EU Paediatric Regulation. 2017. Available from https://ec.europa.eu/health/
sites/health/files/files/paediatrics/docs/2017_childrensmedicines_report_en.pdf.
10. Vassal G, Rousseau R, Blanc P, et al. Creating a unique, multi-stakeholder 
Paediatric Oncology Platform to improve drug development for children and ad-
olescents with cancer. Eur J Cancer. 2015;51(2):218-24. 
KEY MESSAGES FOR CLINICAL PRACTICE
1.  As paediatric cancer is inherently rare, standard of care treatment includes inclusion in a clinical trial when 
possible.
2.  Organisation of clinical trial infrastructure is therefore crucial to ensure optimal care for patients.
3.  Resources provided for this endeavour are limited in Belgium.
4.  Expansion of the medical, paramedical and scientific staff, as well as reimbursement of off-label drugs 
used in the standard of care setting is urgently needed to ensure adhesion to European standards.
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